Channel (cl, Na, K, Ca) Disease - Classification

What is Channel (cl, Na, K, Ca) Disease - Classification?

Channel (cl, Na, K, Ca) Disease - Classification is a rare disease. It is also known as Myotonia caused by channel disease CLASSIFICATION.

Ion channels are made up of subunits with an aqueous pore. They are gaited and might be opened or closed by either ligands attaching themselves to receptors or opened by changes in voltage (Zuberi and Hanna 2001).


Chloride: Congenital myotonia 7q35 CLCN1 (Koch et al., 1992)
(both Thompson and Becker)

Myotonia levior 7q35 CLCN1
Hyperekplexia 5q32 GLRA-1

Sodium: Hyperkalemic periodic paralysis 17q23 SCN4A
Hypokalemic periodic paralysis 17q23 SCN4A (Bulman et al., 1999)
Paramyotonia congenita (PC) 17q23 SCN4A (Ebers et al., 1991)
PC aggrevated by potassium 17q23 SCN4A (Plaster et al., 2001)
Masseter rigidity succinyl choline induced 17q
Long QT 3p21-24 SCN5A (Wang et al., 1995)
Epilepsy - generalised with febrile 19q SCN1B
Epilepsy - generalised with febrile 2q SCN1A

Calcium Hypokalemic periodic paralysis 1q31-q32 CACLN1A3 (Fontaine et al., 1994)
Episodic ataxia type II 19p13 CACNL1A4 (Ophoff et al., 1996)
SCA6 19q13 CACNL1A4
Migraine-hemiplegic 19p13 CACNL1A4
Malignant hyperthermia
Central core disease 19q RYR1
Epilepsy - nocturnal, frontal lobe 20q13 CHRNA4
Epilepsy - nocturnal, frontal lobe 15q24 CHRNA3
Epilepsy-nocturnal, frontal lobe 1p CHRNB2

Potassium Long QT 7q35-36 LQT2 Curran et al., (1995)
Long QT 11p15 LQT1 Wang et al., (1996)
Long QT 21q22 LQT5 Splawski et al., (1997)
Long QT 4q25-4q27 LQT4 Schott et al., (1995)
Myokymia/periodic ataxia 12p13 KCNA1
(episodic ataxia type 1)

Malignant hyperthermia 19q13 RYR1(MHS1)
Malignant hyperthermia 17q11.2-q24 MHS2 probably SCN4A (Levitt et al., (1992)
Malignant hyperthermia 7q21 MHS3 probably CACNL2A (Iles et al., 1994)
Malignant hyperthermia 3q13 MHS4 (Sudbrak et al., 1995)
Malignant hyperthermia 1q31-q32 MHS5 probably CACNL1A3 (Monnier et al., 1997)
Malignant hyperthermia 5p MHS6 (Robinson et al., 1997)
Epilepsy - benign neonatal 20q13 KCNQ2
Epilepsy - benign neonatal 8q24 KCNQ3

Nicotinic acetylcholine receptor

Myasthenia - slow channel disease 17p11 CHRNB (Engel et al., 1996)
Myasthenia - slow channel disease 2q24-2q32 CHRNA (Sine et al., 1995)
Myasthenia - fast channel disease 17p 13 CHRNE (Ohno et al., 1996)

Read More

* This information is courtesy of the L M D.

If you find a mistake or would like to contribute additional information, please email us at: [email protected]

What gene changes cause Channel (cl, Na, K, Ca) Disease - Classification?

The syndrome is inherited in the following inheritance pattern/s:


In some cases, a genetic syndrome may be the result of a de-novo mutation and the first case in a family. In this case, this is a new gene mutation that occurs during the reproductive process.

The syndrome can be caused by mutations in the following gene/s location/s:

What are the main symptoms of Channel (cl, Na, K, Ca) Disease - Classification?

The typical symptoms of the syndrome are:

How does someone get tested for Channel (cl, Na, K, Ca) Disease - Classification?

The initial testing for Channel (cl, Na, K, Ca) Disease - Classification can begin with facial genetic analysis screening, through the FDNA Telehealth telegenetics platform, which can identify the key markers of the syndrome and outline the type of genetic testing needed. A consultation with a genetic counselor and then a geneticist will follow.

Based on this clinical consultation with a geneticist, the different options for genetic testing will be shared and consent will be sought for further testing.

Get Faster and More Accurate Genetic Diagnosis!

More than 250,000 patients successfully analyzed!
Don't wait years for a diagnosis. Act now and save valuable time.

Start Here!

"Our road to a rare disease diagnosis was a 5-year journey that I can only describe as trying to take a road trip with no map. We didn’t know our starting point. We didn’t know our destination. Now we have hope."


Paula and Bobby
Parents of Lillie

What is FDNA Telehealth?

FDNA Telehealth is a leading digital health company that provides faster access to accurate genetic analysis.

With a hospital technology recommended by leading geneticists, our unique platform connects patients with genetic experts to answer their most pressing questions and clarify any concerns they may have about their symptoms.

Benefits of FDNA Telehealth

FDNA icon


Our platform is currently used by over 70% of geneticists and has been used to diagnose over 250,000 patients worldwide.

FDNA icon


FDNA Telehealth provides facial analysis and screening in minutes, followed by fast access to genetic counselors and geneticists.

FDNA icon

Ease of Use

Our seamless process begins with an initial online diagnosis by a genetic counselor and follows by consultations with geneticists and genetic testing.

FDNA icon

Accuracy & Precision

Advanced artificial intelligence (AI) capabilities and technology with a 90% accuracy rate for a more accurate genetic analysis.

FDNA icon

Value for

Faster access to genetic counselors, geneticists, genetic testing, and a diagnosis. As fast as within 24 hours if required. Save time and money.

FDNA icon

Privacy & Security

We guarantee the utmost protection of all images and patient information. Your data is always safe, secure, and encrypted.

FDNA Telehealth can bring you closer to a diagnosis.
Schedule an online genetic counseling meeting within 72 hours!